Pfizer

J.P. Morgan Healthcare Conference

Ian Read Chairman and Chief Executive Officer

January 10, 2012

Forward-Looking Statements and Non-GAAP Financial Information

● Our discussions during this conference will include forward-looking

statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2010 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.

● Also, the discussions during this conference will include certain financial , g

measures that were not prepared in accordance with U.S. generally accepted accounting principles. Reconciliations of those non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures can be found in Pfizer’s Current Report on Form 8-K dated November 1, 2011. "Investors—SEC Filings" section.

● These reports are available on our website at www.pfizer.com in the

J.P. Morgan Healthcare Conference

Improving the Performance of the Innovative Core

“Sustainable Pipeline Engine”

Capitalize on Near-Term Opportunities  Prevnar 13

TM

Advance the Late-Stage Pipeline  Dacomitinib (Lung Cancer)  Inotuzumab (Lymphoma)  Meningococcal B Vaccine  Bapineuzumab (Alzheimer’s Disease)  Tofacitinib (Ulcerative Colitis, Psoriasis and Crohn’s Disease)

Develop the Next Wave of Compounds  PCSK9 (Hyperlipidemia)  GkA (Diabetes)  MadCam, IL6 (Inflammation)  NaV 1.7 Ion Channels (Pain)  PDE5 Inhibitor (Diabetic Nephropathy and Stroke)  S. Aureus Vaccine

for Adults

 Tofacitinib (RA)  Xalkori® (crizotinib)  Inlyta® (axitinib)  Eliquis (apixaban)

TM

Depth and Breadth of Current Pipeline Position Us Well for the Future

J.P. Morgan Healthcare Conference

Improving the Rigor and Productivity of R&D

● Focusing on therapeutic areas where we believe we have the right elements for

success

 Neuroscience, CVMED, Oncology, Inflammation...